🔗 Share this article

While the US undertakes unprecedented changes to its vaccination schedules, a particular individual has surfaced somewhat surprisingly: Tracy Beth Høeg, a US-based sports physician and public health researcher who first made her name by expressing skepticism about Covid vaccines in the pandemic and has zeroed in on alleged fatalities after Covid immunization in her short position at the Food and Drug Administration.

Scheduled Shifts to Childhood Vaccine Schedule

Health officials were set to announce major changes to the childhood vaccination calendar earlier this month, synchronizing the US with the Danish immunization schedule, sources say – a substantial departure that would place the US out of step with much of the international standard with no evidence for improved outcomes. This reveal has been postponed until the next year.

Rather than Vinay Prasad, Dr. Høeg is scheduled to speak at the gathering. She was recently named acting director of the FDA’s Center for Drug Evaluation and Research (CDER), the fifth individual to lead the center this year.

A Shift at the Regulatory Body

Høeg's temporary position may indicate a closer partnership between the drug and biologics centers as Dr. Høeg and Prasad consolidate power at the FDA – and it signals a greater focus upon rolling back long-standing immunizations at the FDA.

Høeg has repeatedly called for discontinuing some pediatric immunization guidelines in the US in order to be more in line with Denmark's approach, a country with nationalized medicine and a number of inhabitants approximately the size of the state of Wisconsin.

To date statements, she has continued to focus on vaccines – typically the domain of Dr. Prasad, chief of the FDA’s Center for Biologics Evaluation and Research (CBER) – as opposed to medication approval.

Questions Over Background

Høeg has no obvious background in drug development, approval processes or administrative roles, which has been typical for past heads of the biologics center. She has worked at the FDA as a key advisor to the FDA chief and the vaccine center since spring.

“She doesn’t seem to have the necessary background” for running the CDER, remarked Dr. Jonathan Howard. “She’s never run a scientific study. She has no expertise in running a sizeable institution. She has no expertise in industry regulation.”

Previous directors of CBER would “understand legal statutes and the science of pharmaceutical innovation”, noted a former acting FDA commissioner. “Clearly, she has not acquired the sort of resume that prior appointees who led the center have had.”

The drug center has an vast range of responsibilities at the FDA, Woodcock stated.

“Many people just zeroes in on the new drug program, but the off-patent medication office authorizes numerous off-brand pharmaceuticals. There’s a biosimilars division, non-prescription drug unit and more, and each of these have to be supervised,” Dr. Woodcock explained. “The responsibility you don’t keep your eye on, that’s the thing that I always told people is going to cause problems.”

Additionally, a significant management element to the job, which manages more than 5,000 personnel. “It’s a massive administrative position, if you do it right,” she added.

Response and Disputed Policies

Regarding inquiries about Høeg’s qualifications and whether this appointment represents increased cooperation among FDA leaders on vaccines, a spokesperson said that the “concerns rely on flawed presumptions”.

“Her resume is consistent with the responsibilities of her job,” the representative said, citing the months Høeg spent guiding the FDA commissioner on “drug safety and approval science, including computerized risk analysis and immunization monitoring”.

As the temporary head, Dr. Høeg inherits the agency head's controversial expedited review system, a controversial rapid drug-approval program that allegedly concerned her predecessors. “By what process are these drugs being selected for this expedited pathway? Who makes the choices?” Howard said. “There’s a lot of lack of transparency going on at the regulatory body right now.”

In general, he said, “the agency seems to be moving towards more relaxed oversight of all drugs, with the exception of vaccines.”

Public Past Work on Immunizations

With vaccines, Høeg has a more established, if problematic, past, some experts observe. She published a research paper using unconfirmed volunteer-provided data to assess the frequency of myocarditis following Covid vaccination. She counseled the Florida top health official Dr. Joseph Ladapo, who allegedly have altered data to imply COVID-19 vaccines are pose a greater threat than they are.

Among her “desired changes” for the incoming federal leadership encompassed changing rules for novel immunizations and discontinuing “optional” vaccines, she stated post-election on a online show. At the agency, Dr. Høeg has allegedly proposed barring teenage boys from receiving Covid vaccinations.

“She’s an all-around true believer who begins with her beliefs and tailors the evidence to fit the data in a highly deceptive, dishonest manner,” Dr. Howard argued.

Gaining Influence and a “Revenge Tour”

Dr. Høeg aligned with other contrarians, {like|